Literature DB >> 8389550

Effect of topoisomerase inhibitors on the in vitro HIV DNA integration reaction.

S Carteau1, J F Mouscadet, H Goulaouic, F Subra, C Auclair.   

Abstract

Retroviral growth requires as an obligatory step the integration of a DNA copy of the viral RNA into the genomic DNA of the host. Recombinant human immunodeficiency virus type I (HIV-1) integrase (IN) expressed in Escherichia coli efficiently catalyzes the overall in vitro integration reaction, namely, the processing of the LTR ends and the strand transfer reaction. Using the 3' end of synthetic oligonucleotides which match the termini of the HIV-I U5 LTR as substrate and supercoiled pSP65 DNA as target, we have measured the effect of various topoisomerase inhibitors on the functional activity of the IN protein. Among the various drugs tested, the antitumor drug 2N-Methyl, 9-hydroxyellipticinium (NMHE) displays a marked inhibitory effect on the IN-catalyzed U5 insertion. This effect is related to the DNA binding properties of the drug rather than to a selective effect on the IN protein or the DNA-IN protein complex.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8389550     DOI: 10.1006/bbrc.1993.1573

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules.

Authors:  C M Farnet; B Wang; J R Lipford; F D Bushman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

2.  Human immunodeficiency virus type 1 cDNA integration: new aromatic hydroxylated inhibitors and studies of the inhibition mechanism.

Authors:  C M Farnet; B Wang; M Hansen; J R Lipford; L Zalkow; W E Robinson; J Siegel; F Bushman
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

3.  Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase.

Authors:  B McDougall; P J King; B W Wu; Z Hostomsky; M G Reinecke; W E Robinson
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

4.  Equivalent inhibition of half-site and full-site retroviral strand transfer reactions by structurally diverse compounds.

Authors:  D Hazuda; P Felock; J Hastings; B Pramanik; A Wolfe; G Goodarzi; A Vora; K Brackmann; D Grandgenett
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

5.  Irreversible inhibition of human immunodeficiency virus type 1 integrase by dicaffeoylquinic acids.

Authors:  K Zhu; M L Cordeiro; J Atienza; W E Robinson; S A Chow
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

6.  Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase.

Authors:  P Levy-Mintz; L Duan; H Zhang; B Hu; G Dornadula; M Zhu; J Kulkosky; D Bizub-Bender; A M Skalka; R J Pomerantz
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

7.  Differential divalent cation requirements uncouple the assembly and catalytic reactions of human immunodeficiency virus type 1 integrase.

Authors:  D J Hazuda; P J Felock; J C Hastings; B Pramanik; A L Wolfe
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

8.  Inhibition of human immunodeficiency virus integrase by bis-catechols.

Authors:  R L LaFemina; P L Graham; K LeGrow; J C Hastings; A Wolfe; S D Young; E A Emini; D J Hazuda
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

9.  Inhibition of human immunodeficiency virus type 1 integrase by 3'-azido-3'-deoxythymidylate.

Authors:  A Mazumder; D Cooney; R Agbaria; M Gupta; Y Pommier
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

10.  FEDS: a Novel Fluorescence-Based High-Throughput Method for Measuring DNA Supercoiling In Vivo.

Authors:  Alexandre Duprey; Eduardo A Groisman
Journal:  mBio       Date:  2020-07-28       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.